Press release
Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report
* In September 2024:- Bayer - A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).
* DelveInsight's Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
* The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
* Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab , and others.
Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer Emerging Drugs
* Niraparib: Janseen
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
* Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravitreal
* Subretinal
* Topical.
* Molecule Type
Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Castrate Resistant Prostrate Cancer Pipeline Report
* Coverage- Global
* Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
* Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Castrate Resistant Prostrate Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Castrate Resistant Prostrate Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Castrate Resistant Prostrate Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Niraparib: Janseen
* Mid Stage Products (Phase II)
* ZEN003694: Newsoara Biopharma
* Early Stage Products (Phase I)
* EPI7386: ESSA Pharma
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Castrate Resistant Prostrate Cancer Key Companies
* Castrate Resistant Prostrate Cancer Key Products
* Castrate Resistant Prostrate Cancer- Unmet Needs
* Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
* Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
* Castrate Resistant Prostrate Cancer Analyst Views
* Castrate Resistant Prostrate Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castrate-resistant-prostrate-cancer-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 here
News-ID: 3661647 • Views: …
More Releases from ABNewswire
Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data …
Tirunelveli, India - 30 August, 2025 - When global enterprises need to migrate their Microsoft 365 environments, failure isn't an option. A single misstep can mean lost data, broken workflows, and frustrated teams. Today, Apps4.Pro-trusted by over 15,000 organizations worldwide-announces the enhanced Migration Manager platform that's redefining what's possible in tenant-to-tenant migration.
From Fortune 500 giants like Siemens Energy and Johnson & Johnson to fast-scaling startups, organizations are discovering a migration…
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs I …
Brandon, FL - Homeowners in Brandon, Florida, are facing increased pressure to replace aging roofs as insurance companies tighten coverage requirements. Dynamic Roofing Concepts provides roof replacement in Brandon, FL [https://www.dynamicroofingconcepts.com/] and has seen increased demand as local homeowners face pressure from insurance companies to replace aging roofs.
In Florida, most homeowners are aware that old roofs are more vulnerable to wind and water damage. Insurance providers have responded by requiring…
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential.
Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that…
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Ho …
Discover how Palm Coast Pest Control uses eco-friendly solutions to protect Jupiter, FL homes from pests while maintaining a healthy, chemical-free environment.
Jupiter, FL - As residents of Jupiter, FL, seek effective and sustainable solutions to pest problems, Palm Coast Pest Control stands out as a trusted provider of eco-friendly pest control services. The company has earned a reputation for its commitment to keeping homes safe, healthy, and pest-free while also…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
